肝细胞癌的综合介入治疗

白苇; 韩国宏

肝细胞癌的综合介入治疗

白苇,
韩国宏

第四军医大学西京消化病医院消化介入科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 3550
- HTML全文浏览量: 16
- PDF下载量: 787
- 被引次数: 0
出版历程
- 出版日期: 2013-01-20

Comprehensive intervention treatment for hepatocellular carcinoma

摘要

摘要:
肝细胞癌(HCC)是世界范围内第五大常见肿瘤,每年新增病例超过50万。由于HCC早期症状隐匿,大多数患者在确诊时已是中晚期,失去了接受治愈性治疗的机会。而中晚期HCC患者由于肝功能损伤及肿瘤进展致预后很差,目前,以肝动脉栓塞化疗术(TACE)为主的综合介入治疗已成为中晚期HCC的主要治疗方式。本文就HCC的综合介入治疗的最新进展综述如下。
- 肝肿瘤 /
- 肝动脉栓塞化疗术 /
- 射频消融
Abstract:
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and more than half a million new cases are reported each year.Due to the absence of clinical symptoms in the early stage, the majority of patients are diagnosed at the intermediate/advanced stage when curative treatment options are limited.The prognosis of patients with intermediate/advanced HCC is poor because of the high potential for liver function damage and tumor progression.Combination therapies involving transarterial chemoembolization (TACE) have become the main treatments used in intermediate/advanced HCC.This comprehensive review discusses the latest progress in research of interventional treatments for HCC and their implications for the intermediate/advanced HCC patients particularly.
- liver neoplasms /
- transarterial chemoembolization /
- radiofrequency ablation

HTML全文

参考文献(21)

[1]Bruix J, Sala M, Llovet JM, et al.Chemoembolization for hepa-tocellular carcinoma[J].Gastroenterology, 2004, 127 (5) :S179-S188.

[2]Llovet JM, Bruix J.Systematic review of randomized trials forunresectable hepatocellular carcinoma:chemoembolization im-proves survival[J].Hepatology, 2003, 37 (2) :429-442.

[3]Poyanli A, Rozanes I, Acunas B, et al.Palliative treatment ofhepatocellular carcinoma by chemoembolization[J].ActaRadiol, 2001, 42 (6) :602-607.

[4]Kameyama M, Imaoka S, Fukuda I, et al.Delayed washoutof intratumor blood flow is associated with good response tointraarterial chemoembolization for liver metastasis of colorec-tal cancer[J].Surgery, 1993, 114 (1) :97-101.

[5]Sergio A, Cristofori C, Cardin R, et al.Transcatheter Arterialchemoembolization (TACE) in hepatocellular carcinoma (HCC) :the role of angiogenesis and invasiveness[J].Am JGastroenterol, 2008, 103 (4) :914-921.

[6]Barnett BP, Liapi E, Kim GK, et al.PEGDA based spheres-chemospheres[C]//SIR Annual Meeting.DC, USA, 2008.

[7]赵艳, 韩国宏, 白苇, 等.药物缓释微球肝动脉化疗栓塞治疗肝癌研究进展[J].介入放射学杂志, 2012, 21 (4) :94-98.

[8]Sangro B, Bibao JI, Boan J, et al.Radioembolization using90Y-resin microspheres for patients with advanced hepato-cellular carcinoma[J].Int J Radiat Oncol Biol Phys, 2006, 66 (3) :792-800.

[9]Salem R, Lewandowski RJ, Atassi B, et al.Treatment ofunresectable hepatocellular carcinoma with use of 90Y micro-spheres (TheraSphere) :Safety, tumor response, and sur-vival[J].J Vasc Interv Radiol, 2005, 16 (2) :1627-1639.

[10]Sangro B, Carpanese L, Cianni R, et al.Survival after yttri-um-90 resin microsphere radioembolization of hepatocellularcarcinoma across barcelona clinic liver cancer stages:a euro-pean evaluation[J].Hepatology, 2011, 54 (3) :868-878.

[11]Salem R, Lewandowski RJ, Kulik L, et al.Radioembolizationresults in longer time-to-progression and reduced toxicitycompared with chemoembolization in patients with hepato-cellular carcinoma[J].Gastroenterology, 2011, 140 (2) :497-507.

[12]Carr BI, Kondraqunta V, Buch SC, et al.Therapeutic equiva-lence in survival for hepatic arterial chemoembolization andyttrium 90 microspheres treatments in unresectable hepato-cellular carcinoma:a two-cohort study[J].Cancer, 2010, 116 (5) :1305-1314.

[13]刘允怡, 赖俊雄, 刘晓欣, 等.钇90微球治疗原发性肝癌[J].临床肝胆病杂志, 2011, 4 (27) :348-350.

[14]Monsky WL, Kruskal JB, Lukyanov AN, et al.Radiofrequen-cy ablation increases intratumoral liposomal doxorubicin accu-mulation in an animal breast tumor model[J].Radiology, 2002, 224 (3) :823-829.

[15]陈敏山, 刘芙蓉.射频消融在肝癌多学科综合治疗中的应用[J].临床肝胆病杂志, 2011, 27 (4) :368-371.

[16]Pompili M, Mirante VG, Rondinara G, et al.Percutaneousablation procedures in cirrhotic patients with hepatocellularcarcinoma submitted to liver transplantation:assessment ofefficacy at explant analysis of safety for tumor recurrence[J].Liver Transpl, 2005, 11 (9) :1117-1126.

[17]Kim JW, Kim JH, Won HJ, et al.Hepatocellular carcinomas2-3cm indiameter:transarterial chemoembolization plus ra-diofrequency ablation vs radiofrequency ablation alone[J].Eur J Radiol, 2011, 81 (3) :189-193.

[18]Llovet JM, Ricci S, Mazzaferro V, et al.Sorafenib in ad-vanced hepatocellular carcinoma[J].N Engl J Med, 2008, 359 (4) :378-390.

[19]Strebel BM, Dufour JF.Combined approach to hepatocellularcarcinoma:a new treatment concept for nonresectable dis-ease[J].Expert Rev Anticancer Ther, 2008, 8 (11) :1743-1749.

[20]Park JW, Koh YH, Kim HY, et al.Phase II study of concur-rent transarterial chemoembolization and sorafenib in patientswith unresectable hepatocellular carcinoma[J].J Hepatol, 2012, 56 (6) :1336-1342.

[21]Pawlik TM, Reyes DK, Cosgrove D, et al.Phase II trial ofsorafenib combined with concurrent transarterial chemoem-bolization with drug-eluting beads for hepatocellular carcino-ma[J].J Clin Oncol, 2011, 29 (30) :3960-3967.

施引文献

资源附件(0)

访问统计